A groundbreaking prostate cancer test developed in the UK may allow up to 80 percent of men to avoid invasive biopsies, according to a recent study. The test, called EpiSwitch PSE, uses advanced technology to detect prostate cancer with remarkable accuracy, offering a less stressful and safer alternative to traditional diagnostic methods.
How the Test Works
EpiSwitch PSE is a next-generation blood test created by Oxford BioDynamics. It is designed to be used following a PSA test, which measures prostate-specific antigen levels in the blood. Elevated PSA levels can indicate prostate issues, including cancer, but traditional PSA testing alone is only about 50 percent accurate.
The new test examines five genetic markers to determine the likelihood that cancer is present, achieving an accuracy rate of 94 percent. This is a significant improvement over standard PSA testing, which can often lead to unnecessary biopsies and anxiety for patients.
Study Findings
The peer-reviewed study, published in the journal Cancers, concluded that up to 79.1 percent of patients could safely defer biopsies based on EpiSwitch PSE results. Researchers emphasized that the test maintains diagnostic safety while reducing invasive procedures. By avoiding unnecessary biopsies, men face less physical risk and psychological stress, a barrier that often discourages men from seeking testing in the first place.
Expert Commentary
Dr. Alexandre Akoulitchev, chief scientific officer at Oxford BioDynamics, said, “This study builds on our earlier clinical validation work and demonstrates that EpiSwitch PSE is a precise, minimally invasive test. It empowers clinicians and patients with clarity, reduces patient risk, and improves outcomes, while easing pressure on diagnostic pathways.”
Oliver Kemp, chief executive of UK charity Prostate Cancer Research (PCR), added, “Reducing unnecessary biopsies and scans means less stress for men and more capacity in the healthcare system. Smarter testing can save millions while improving patient care.”
Potential Impact on Healthcare
The study suggested that widespread adoption of the test could significantly reduce costs for the National Health Service (NHS). By lowering the number of biopsies and MRI scans, each patient could potentially save nearly £1,000. This could free up resources, reduce wait times, and improve access for other patients needing care.
Support for National Screening
The EpiSwitch PSE test has garnered support from prominent figures in the UK. Former Prime Minister Rishi Sunak visited Oxford BioDynamics and advocated for a targeted national screening program for men most at risk of prostate cancer. Sir Stephen Fry, a prostate cancer survivor, has also backed calls for broader testing initiatives to detect cancer earlier and prevent unnecessary deaths.
Prostate cancer often affects men with a family history of the disease or those of African descent. The cancer can develop silently, making early detection crucial for successful treatment.
Conclusion
The EpiSwitch PSE blood test represents a significant advancement in prostate cancer screening. By combining it with PSA testing, clinicians can reduce the need for invasive biopsies, lower healthcare costs, and improve patient experience. With continued research and national support, this innovation could transform prostate cancer detection and care, making screening safer, simpler, and more effective for men at risk.
YOU MAY ALSO LIKE
Prostate Cancer Awareness: Why a PSA Test Could Save Your Life
PSA Test Saves Lives: Cancer Survivor Urges Men This Autumn
PSA Test: New Efforts to Tackle Prostate Cancer in Philadelphia
